期刊
NEUROBIOLOGY OF AGING
卷 32, 期 -, 页码 S4-S9出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2011.09.003
关键词
Alzheimer's disease; CSF; Tau; Biomarkers
资金
- Eli Lilly
- Pfizer
- Astra-Zeneca
- C2N Diagnostics
- NIH [AG03991, AG026276]
Over the past 15 years, cerebrospinal fluid (CSF) biomarkers have been shown to be useful for both the diagnosis as well as the prognosis in Alzheimer's disease. It has been shown the CSF levels of amyloid-beta (A beta)(42) are a very good marker for the presence of amyloid deposition in the brain regardless of clinical status and that total tau and phosphorylated forms of tau are useful in detection of neurodegeneration. When combined together, these CSF markers are useful not only in differential diagnosis but also in predicting conversion and rate of progression from mild cognitive impairment/very mild dementia to more severe impairment. The markers are also useful in predicting conversion from cognitive normalcy to very mild dementia. This field is briefly reviewed and recommendations for future studies in this area are provided. (C) 2011 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据